Načítá se...

A review of the efficacy and safety of denosumab in postmenopausal women with osteoporosis

Denosumab, a fully human monoclonal antibody to RANK ligand [RANK-L]) was approved for the treatment of postmenopausal osteoporosis in June 2010, and is highly effective in reducing the risk of vertebral, nonvertebral, and hip fracture risk. The registration of denosumab was the culmination of the d...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autor: Miller, Paul D.
Médium: Artigo
Jazyk:Inglês
Vydáno: SAGE Publications 2011
Témata:
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3383499/
https://ncbi.nlm.nih.gov/pubmed/22870485
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1759720X11424220
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!